plerixafor has been researched along with Ache in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bolwell, BJ; DiPersio, JF; Marulkar, S; Maziarz, RT; Micallef, IN; Nademanee, AP; Partisano, AM; Stadtmauer, EA; Stiff, PJ | 1 |
| Abdelhak, B; Frietag, C; Menichella, DM; Miller, RJ; Ren, D; Shum, A | 1 |
| Assanelli, A; Bellio, L; Ciceri, F; Coppola, M; Corti, C; De Freitas, T; Gattillo, S; Malabarba, L; Malato, S; Marktel, S; Milani, R; Rizzo, L | 1 |
| Li, XQ; Ma, H; Sun, XJ; Tan, WF; Zhang, ZL | 1 |
1 trial(s) available for plerixafor and Ache
| Article | Year |
|---|---|
Plerixafor on demand in ten healthy family donors as a rescue strategy to achieve an adequate graft for stem cell transplantation.
Topics: Adult; Aged; Allografts; Antigens, CD34; Benzylamines; Blood Cell Count; Carcinoma, Renal Cell; Colony-Forming Units Assay; Cyclams; Drug Synergism; Female; Graft Survival; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Heterocyclic Compounds; Humans; Kidney Neoplasms; Lenograstim; Leukapheresis; Leukemia, Myeloid, Acute; Living Donors; Male; Middle Aged; Pain; Parents; Peripheral Blood Stem Cell Transplantation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recombinant Proteins; Siblings; Treatment Outcome | 2015 |
3 other study(ies) available for plerixafor and Ache
| Article | Year |
|---|---|
Safety and efficacy of upfront plerixafor + G-CSF versus placebo + G-CSF for mobilization of CD34(+) hematopoietic progenitor cells in patients ≥60 and <60 years of age with non-Hodgkin's lymphoma or multiple myeloma.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzylamines; Blood Cell Count; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Cyclams; Double-Blind Method; Gastrointestinal Diseases; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Lymphoma, Non-Hodgkin; Middle Aged; Multiple Myeloma; Neutropenia; Pain; Peripheral Blood Stem Cell Transplantation; Transplantation, Autologous; Young Adult | 2013 |
CXCR4 chemokine receptor signaling mediates pain in diabetic neuropathy.
Topics: Animals; Benzylamines; Cells, Cultured; Cyclams; Diabetes Mellitus, Type 2; Diet, High-Fat; Disease Models, Animal; Ganglia, Spinal; Gene Expression Regulation; GTPase-Activating Proteins; Guanine Nucleotide Exchange Factors; Heterocyclic Compounds; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Pain; Pain Measurement; Pain Threshold; Receptors, CXCR4; Receptors, Leptin; Sensory Receptor Cells; Signal Transduction | 2014 |
Down-Regulation of CXCL12/CXCR4 Expression Alleviates Ischemia-Reperfusion-Induced Inflammatory Pain via Inhibiting Glial TLR4 Activation in the Spinal Cord.
Topics: Animals; Astrocytes; Behavior, Animal; Benzylamines; Chemokine CXCL12; Cyclams; Down-Regulation; Heterocyclic Compounds; Hyperalgesia; Inflammation; Microglia; Pain; Rats; Rats, Sprague-Dawley; Receptors, CXCR4; Reperfusion Injury; Spinal Cord; Sulfonamides; Toll-Like Receptor 4 | 2016 |